Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD): Evolving Insights into Pathogenesis, Progression, and Personalized Treatment Approaches
DOI:
https://doi.org/10.12775/QS.2025.43.61408Keywords
MASLD, Pathogenesis, Anti-obesity drugs, Tirzepatide, GLP-1 receptor agonist, Semaglutide, fibrosisAbstract
Background:
Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD), previously classified under non-alcoholic fatty liver disease (NAFLD), is an increasingly prevalent chronic liver disorder tightly linked to obesity, insulin resistance, and systemic metabolic dysfunction. It ranges from simple steatosis to nonalcoholic steatohepatitis (MASH), fibrosis, cirrhosis, and hepatocellular carcinoma.
Objective:
This review explores the current understanding of MASLD, emphasizing its multifactorial etiology, evolving pathophysiological mechanisms, clinical progression, and therapeutic strategies, including emerging pharmacological and lifestyle interventions.
Methods:
A structured review of peer-reviewed articles published between 2019 and 2025 was conducted using critical analysis of uploaded and curated literature focusing on MASLD’s pathogenesis, comorbidities, and treatment modalities.
Findings:
MASLD is driven by a combination of genetic, environmental, metabolic, and immunological factors. Recent insights into lipid dysregulation, gut-liver axis, immune modulation, and endocrine pathways have clarified mechanisms of disease progression. Weight loss remains a cornerstone of management, supported by emerging anti-obesity medications such as GLP-1 receptor agonists and dual agonists. Novel therapies targeting hepatic stellate cells, fibroinflammatory signaling, and microbiota-derived metabolites represent future avenues for precision-based treatment.
Conclusion:
Effective MASLD management necessitates an integrated approach combining lifestyle interventions, pharmacotherapy, and targeted therapeutics based on individual phenotypes. Continued research into molecular pathways and personalized strategies holds promise for disease reversal and improved patient outcomes.
References
Portincasa, P., Khalil, M., Mahdi, L., Perniola, V., Idone, V., Graziani, A., Baffy, G., & Di Ciaula, A. (2024). Metabolic dysfunction–associated steatotic liver disease: From pathogenesis to current therapeutic options. International Journal of Molecular Sciences, 25(11), 5640. https://doi.org/10.3390/ijms25115640
Stefan, N., Yki-Järvinen, H., & Neuschwander-Tetri, B. A. (2025). Metabolic dysfunction-associated steatotic liver disease: heterogeneous pathomechanisms and effectiveness of metabolism-based treatment. The Lancet Diabetes & Endocrinology, 13(2), 134–148. https://doi.org/10.1016/S2213-8587(24)00318-8
Zhang, R., Yan, Z., Zhong, H., Luo, R., Liu, W., Xiong, S., Liu, Q., & Liu, M. (2024). Gut microbial metabolites in MASLD: Implications of mitochondrial dysfunction in the pathogenesis and treatment. Hepatology Communications, 8, e0484. https://doi.org/10.1097/HC9.0000000000000484
Li, Y., Yang, P., Ye, J., Xu, Q., Wu, J., & Wang, Y. (2024). Updated mechanisms of MASLD pathogenesis. Lipids in Health and Disease, 23, Article 117. https://doi.org/10.1186/s12944-024-02108-x
Yu, L., Gao, F., Li, Y., Su, D., Han, L., Li, Y., Zhang, X., & Feng, Z. (2024). Role of pattern recognition receptors in the development of MASLD and potential therapeutic applications. Biomedicine & Pharmacotherapy, 175, 116724. https://doi.org/10.1016/j.biopha.2024.116724
Phoolchund, A. G. S., & Khakoo, S. I. (2024). MASLD and the development of HCC: Pathogenesis and therapeutic challenges. Cancers, 16(2), 259. https://doi.org/10.3390/cancers16020259
Shen, J., Xie, E., Shen, S., Song, Z., Li, X., Wang, F., & Min, J. (2024). Essentiality of SLC7A11-mediated nonessential amino acids in MASLD. Science Bulletin, 69(30), 3700–3716. https://doi.org/10.1016/j.scib.2024.09.019
Syed-Abdul, M. M. (2024). Lipid metabolism in metabolic-associated steatotic liver disease (MASLD). Metabolites, 14(1), Article 12. https://doi.org/10.3390/metabo14010012
Meyer, M., Schwärzler, J., Jukic, A., & Tilg, H. (2024). Innate immunity and MASLD. Biomolecules, 14(4), 476. https://doi.org/10.3390/biom14040476
Abdelnabi, M. N., Hassan, G. S., & Shoukry, N. H. (2024). Role of the type 3 cytokines IL-17 and IL-22 in modulating metabolic dysfunction-associated steatotic liver disease. Frontiers in Immunology, 15, Article 1437046. https://doi.org/10.3389/fimmu.2024.1437046
Shrestha, S., Jeon, J.-H., & Hong, C.-W. (2025). Neutrophils in MASLD and MASH. BMB Reports, 58(3), 116–123. https://doi.org/10.5483/BMBRep.2024-0058
Benede-Ubieto, R., Cubero, F. J., & Nevzorova, Y. A. (2024). Breaking the barriers: The role of gut homeostasis in Metabolic-Associated Steatotic Liver Disease (MASLD). Gut Microbes, 16(1), Article 2331460. https://doi.org/10.1080/19490976.2024.2331460
Min, B. H., Devi, S., Kwon, G. H., Gupta, H., Jeong, J.-J., Sharma, S. P., ... & Suk, K. T. (2024). Gut microbiota-derived indole compounds attenuate metabolic dysfunction-associated steatotic liver disease by improving fat metabolism and inflammation. Gut Microbes, 16(1), Article 2307568. https://doi.org/10.1080/19490976.2024.2307568
Hutchison, A. L., Tavaglione, F., Romeo, S., & Charlton, M. (2023). Endocrine aspects of metabolic dysfunction-associated steatotic liver disease (MASLD): Beyond insulin resistance. Journal of Hepatology, 79(6), 1524–1541. https://doi.org/10.1016/j.jhep.2023.08.030
Provera, A., Vecchio, C., Sheferaw, A. N., Stoppa, I., Pantham, D., Dianzani, U., & Sutti, S. (2024). From MASLD to HCC: What’s in the middle? Heliyon, 10(8), e35338. https://doi.org/10.1016/j.heliyon.2024.e35338
Sandireddy, R., Sakthivel, S., Gupta, P., Behari, J., Tripathi, M., & Singh, B. K. (2024). Systemic impacts of metabolic dysfunction-associated steatotic liver disease (MASLD) and metabolic dysfunction-associated steatohepatitis (MASH) on heart, muscle, and kidney related diseases. Frontiers in Cell and Developmental Biology, 12, Article 1433857. https://doi.org/10.3389/fcell.2024.1433857
Mollace, R., Longo, S., Nardin, M., Tavernese, A., Musolino, V., Cardamone, A., ... & Federici, M. (2024). Role of MASLD in CVD: A review of emerging treatment options. Diabetes Research and Clinical Practice, 217, Article 111891. https://doi.org/10.1016/j.diabres.2024.111891
Shi, Y., Taherifard, E., Saeed, A., & Saeed, A. (2024). MASLD-Related HCC: A comprehensive review of the trends, pathophysiology, tumor microenvironment, surveillance, and treatment options. Current Issues in Molecular Biology, 46, 5965–5983. https://doi.org/10.3390/cimb46060356
Hu, S., Wang, Z., Zhu, K., Shi, H., Qin, F., Zhang, T., ... & Li, H. (2025). USP29 alleviates the progression of MASLD by stabilizing ACSL5 through K48 deubiquitination. Clinical and Molecular Hepatology, 31, 147–165. https://doi.org/10.3350/cmh.2024.0478
Chan, W.-K., Chuah, K.-H., Rajaram, R. B., Lim, L.-L., Ratnasingam, J., & Vethakkan, S. R. (2023). Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD): A state-of-the-art review. Journal of Obesity & Metabolic Syndrome, 32(3), 197–213. https://doi.org/10.7570/jomes23052
Melemkiaer, L., Dijkstra, M., Mantovani, A., Byrne, C. D., Targher, G. (2024). Management of cardiovascular risk in patients with metabolic dysfunction-associated steatotic liver disease. European Journal of Internal Medicine, 122, 28–34. https://doi.org/10.1016/j.ejim.2023.11.012
Wu, S., Zhang, L., Yu, L., Fang, H., Liu, X., Lu, F. (2023). Association between diet soft drink consumption and metabolic dysfunction-associated steatotic liver disease: findings from the NHANES. Nutrients, 15(4), Article 764. https://doi.org/10.1186/s12889-023-17223-0
Cezac, C., Popa, L. G., Radulescu, D. M., Dumitrascu, D. L. (2024). Celiac Disease, Gluten-Free Diet and Metabolic Dysfunction-Associated Steatotic Liver Disease. Nutrients, 16(2), Article 237. https://doi.org/10.3390/nu16132008
Malakmahmoudi, A., Leclercq, E., Pégorier, N., Polak, R., Masri, F. (2024). Dietary Rhythms and MASLD-Related Hepatocellular Carcinoma. Cancers, 16(4), Article 765. https://doi.org/10.3390/cancers16203481
Xiang, Y., Zhang, W., Tang, Y., Liu, C., Wei, Y., Zhao, F. (2024). Inappropriate Diet Exacerbates Metabolic Dysfunction-Associated Steatotic Liver Disease via Abdominal Obesity. Journal of Clinical Lipidology, 18(1), 56–67. https://doi.org/10.1002/ueg2.12525
Zeng, J., Wang, X., Zhang, L., Wu, Y., Zhang, W., Shen, W., Lin, Y., Sun, Y., Luo, F. (2024). Therapeutic management of metabolic dysfunction-associated steatotic liver disease. Diabetes, Obesity and Metabolism, 26(1), 89–101. https://doi.org/10.1002/ueg2.12525
Ciardullo, S., Muraca, E., Cannistraci, R., Zerbini, F., Perseghin, G. (2024). Advancements in pharmacological treatment of MASLD: a focus on metabolic and liver-targeted interventions. Liver International, 44(1), 25–38. https://doi.org/10.1093/gastro/goae029
Newsome, P. N., Ratziu, V., Rinella, M., Sanyal, A. J., Harrison, S. A., Francque, S., Abdelmalek, M. F., Anstee, Q. M., Bedossa, P., Cusi, K., et al. (2024). Semaglutide 2.4 mg in Participants With Metabolic Dysfunction-Associated Steatohepatitis: Baseline Characteristics and Design of the Phase 3 ESSENCE Trial. Hepatology, 79(4), 1120–1132. https://doi.org/10.1111/apt.18331
Zheng, Q., Li, X., Feng, Y., Yang, S., Chen, X., Wang, C., Li, Q., Wang, X., Lu, C., Jin, Y., et al. (2024). Ursolic acid targets secreted phosphoprotein 1 to regulate Th17 cells against metabolic dysfunction-associated steatotic liver disease. Hepatology Communications, 8(2), 234–246. https://doi.org/10.1002/hep4.2297
Kim, Y., Lee, J., Lee, S., Park, Y., Kang, J., Kim, D., Moon, J. H., Kim, S. (2025). Multi-modal analysis of human hepatic stellate cells identifies novel therapeutic targets for metabolic dysfunction-associated steatotic liver disease. Nature Communications, 16(1), Article 546. https://doi.org/10.1016/j.jhep.2024.10.044
Brouwers, B., Rao, G., Tang, Y., Rodríguez, Á., Glass, L. C., & Hartman, M. L. (2024). Incretin-based investigational therapies for the treatment of MASLD/MASH. Diabetes Research and Clinical Practice, 211, 111675. https://doi.org/10.1016/j.diabres.2024.111675
European Association for the Study of the Liver (EASL), European Association for the Study of Diabetes (EASD), & European Association for the Study of Obesity (EASO). (2024). EASL-EASD-EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD). Journal of Hepatology, 81, 492–542. https://doi.org/10.1016/j.jhep.2024.04.031
Machado, M. V. (2023). MASLD treatment—a shift in the paradigm is imminent. Frontiers in Medicine, 10, 1316284. https://doi.org/10.3389/fmed.2023.1316284
Weghuber, D., Barrett, T., Barrientos-Pérez, M., Gies, I., Hesse, D., Jeppesen, O. K., Kelly, A. S., Mastrandrea, L. D., Sørrig, R., & Arslanian, S.; STEP TEENS Investigators. (2022). Once-weekly semaglutide in adolescents with obesity. New England Journal of Medicine, 387(24), 2245–2257. https://doi.org/10.1056/NEJMoa2208601
Hamza, M., Papamargaritis, D., & Davies, M. J. (2025). Tirzepatide for overweight and obesity management. Expert Opinion on Pharmacotherapy, 26(1), 31–49. https://doi.org/10.1080/14656566.2024.2436595
Weintraub, W. S., Fahey, J. W., Taylor, B., Wilkins, J. T., & Ryan, D. H. (2023). Five-year weight loss maintenance with obesity pharmacotherapy in a diverse population: implications for long-term MASLD management. Obesity, 31(4), 987–1001. https://doi.org/10.1210/clinem/dgad100
Müller, T. D., Blüher, M., Tschöp, M. H., & DiMarchi, R. D. (2022). Anti-obesity drug discovery: advances and challenges. Nature Reviews Drug Discovery, 21, 201–216. https://doi.org/10.1038/s41573-021-00337-8
Melson, E., Ashraf, U., Papamargaritis, D., & Davies, M. J. (2024). What is the pipeline for future medications for obesity? International Journal of Obesity, 49, 433–451. https://doi.org/10.1038/s41366-024-01473-y
Acosta, A., Camilleri, M., Abu Dayyeh, B., Calderon, G., Gonzalez, D., McRae, A., Rossini, W., Singh, S., Burton, D., & Clark, M. M. (2021). Selection of antiobesity medications based on phenotypes enhances weight loss: a pragmatic trial in an obesity clinic. Obesity, 29(4), 662–671. https://doi.org/10.1002/oby.23120
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2025 Paweł Kukiełka, Katarzyna Moliszewska , Joanna Kośka , Kacper Dywan , Michał Błaszkiewicz , Julia Mazurek , Julia Załęcka , Alicja Nowik , Martyna Musiorska , Gabriela Łocik
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
Stats
Number of views and downloads: 257
Number of citations: 0
